Flashback Technologies is commercializing a new vital sign with broad applications in healthcare and human performance – The Compensatory Reserve Index (CRI). Early stage commercialization is underway with two FDA cleared devices. Due to innate compensatory mechanisms, it is well known that humans are able to lose up to 20% of central volume (due to hemorrhage or dehydration) with little change in standard vital signs – until the patient suddenly and oftentimes unexpectedly experiences cardiovascular collapse, when resuscitative therapy is less effective and more difficult to control. Its non-invasive, easy-to-use vital sign monitor trends changes in intravascular volume and estimates an individual’s tolerance to additional volume loss before collapse. Compared to traditional vital signs, CRI provides early insight that enables intervention that can reduce costs, improve outcomes and save lives.

Research Grants 6 show all


$750K
2010

$2.1M
2012

$99.9K
2013

$1.2M
2014

$1.9M
2015

Patents 27show all

  • 18
    A61B - Diagnosis
  • 18
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 5
    G06F - Electric digital data processing
  • 4
    A61M - Devices for introducing media into, or onto, the body
  • 4
    Y02A - Technologies for adaptation to climate change
  • 2
    G06N - Computer systems based on specific computational models
  • 2
    G06Q - Data processing systems or methods, specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes
  • 1
    A61H - Physical therapy apparatus, e.g. devices for locating or stimulating reflex points in the body

Clinical Trials 3show all

SEC Filings show all


6
D

Contact Information

80 Health Park Drive Suite 20
Louisville, CO 80027
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$2,086,3761-102016-09-23Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2016-09-23Series A
2014-11-19$2,086,376Series A